DrugPatentWatch

DrugPatentWatch Archives

You are currently viewing the 2008 archives
Click here to return to the current data set

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: APIDRA

Summary for Tradename: APIDRA

Patents:3
Applicants:1
NDAs:1
Suppliers: see list1
drug
patent expirations by year for
 APIDRA

Pharmacology for Tradename: APIDRA

Ingredient-typeInsulin
Drug ClassInsulin Analog

Clinical Trials for: APIDRA

Comparison of Apidra to Regular Insulin in Hospitalized Patients
Status: Completed Condition: Diabetes Mellitus, Type II

Insulin Glargine "All to Target" Trial
Status: Completed Condition: Diabetes Mellitus, Type 2

Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents
Status: Terminated Condition: Diabetes Type 1

Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin
Status: Completed Condition: Diabetes Mellitus, Type 2

Expanded PK and PD of Insulin Glulisine Versus Insulin Aspart in Healthy Volunteers
Status: Completed Condition: Diabetes

Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting
Status: Terminated Condition: Diabetes Mellitus, Type 2

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
Status: Recruiting Condition: Type 2 Diabetes

The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children
Status: Completed Condition: Type 1 Diabetes Mellitus

Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart
Status: Completed Condition: Type 2 Diabetes Mellitus

Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes
Status: Recruiting Condition: Diabetes During Pregnancy

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Exclusivity Expiration
Sanofi Aventis Us
APIDRA
insulin glulisine recombinant
INJECTABLE; IV (INFUSION)-SC021629Apr 16, 2004RXYes<disabled><disabled>
Sanofi Aventis Us
APIDRA
insulin glulisine recombinant
INJECTABLE; IV (INFUSION)-SC021629Apr 16, 2004RXYes<disabled><disabled>
Sanofi Aventis Us
APIDRA
insulin glulisine recombinant
INJECTABLE; IV (INFUSION)-SC021629Apr 16, 2004RXYes6,221,633<disabled><disabled>
Sanofi Aventis Us
APIDRA
insulin glulisine recombinant
INJECTABLE; IV (INFUSION)-SC021629Apr 16, 2004RXYes6,960,561<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc